News
5d
Pharmaceutical Technology on MSNVertex and NHS England agree reimbursement for AlyftrekVertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...
Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...
NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...
Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...
Hundreds of people with cystic fibrosis are to be offered a once-a-day pill which has been hailed as “life changing” by ...
US biotech major Vertex Pharmaceuticals (Nasdaq: VRTX) has reached a wide-ranging reimbursement deal with NHS England for ...
While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results